Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 08 Sep 2017
At a glance
- Drugs AP 32788 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors ARIAD Pharmaceuticals
- 07 Nov 2016 According to an ARIAD Pharmaceutical media release, data from this trial are expected in 2017.
- 22 Apr 2016 Status changed from not yet recruiting to recruiting.
- 23 Feb 2016 According to an ARIAD Pharmaceuticals media release, status changed from planning to not yet recruiting.